Retatrutide

Retatrutide is not FDA-approved for any use — but unlike most Tier 2 entries, it isn't sparse-evidence either. It has large, completed Phase 3 trials with positive results across its whole registrational program; it just hasn't cleared FDA review yet. This page describes the mechanism and the actual trial data — not dosing or usage guidance, and not a recommendation to use it. Talk to a doctor before considering it.

Retatrutide is a synthetic peptide developed by Eli Lilly that activates three receptors at once: GIP, GLP-1, and glucagon. Semaglutide targets one of these receptors (GLP-1); tirzepatide targets two (GIP and GLP-1). Retatrutide's triple action is the proposed reason for its larger weight-loss effect in trials — the added glucagon-receptor activity increases energy expenditure in addition to the appetite-suppressing and insulin effects the other two receptors provide.

This is real, substantial human data, not a proposed mechanism awaiting proof: as of mid-2026, all four core Phase 3 TRIUMPH registrational trials have reported positive topline results. TRIUMPH-1, in adults with obesity or overweight and at least one weight-related condition but without diabetes, showed an average 28.3% body weight loss on the highest studied dose at 80 weeks. TRIUMPH-4 showed roughly 28.7% average weight loss at 68 weeks. Additional Phase 3 readouts, including maintenance-dosing studies, were expected later in 2026. This puts retatrutide's evidence base in a fundamentally different place than most Tier 2 compounds, which typically have only animal data or small pilot studies.

AJMC — Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 →

Retatrutide is not FDA-approved and not available by prescription as of this writing. Eli Lilly has indicated it plans to file a Biologics License Application in early 2027; on a standard ~10-month FDA review timeline, the earliest realistic approval decision would land in 2028, though a priority review could shorten that. This status is likely to change as more Phase 3 data reads out and a filing is submitted — check back for updates rather than treating this page as a permanent classification. Until any approval, it remains available only through unregulated research-chemical channels, which carry all the sourcing and purity risks that implies regardless of how strong the underlying trial data looks.

PharmExec — Lilly's Retatrutide Displays Positive Topline Results in Successful Phase III Trial